Zoqlam, Randa;
Lazauskaite, Sandra;
Glickman, Scott;
Zaitseva, Lyubov;
Ilie, Petre-Cristian;
Qi, Sheng;
(2022)
Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases.
European Journal of Pharmaceutical Sciences
, 173
, Article 106167. 10.1016/j.ejps.2022.106167.
Preview |
Text
Emerging molecular mechanisms and genetic targets for developing novel.pdf - Other Download (6MB) | Preview |
Abstract
Bladder diseases affect millions of patients worldwide and compromise their quality of life with a substantial economic impact. The not fully understood aetiologies of bladder diseases limit the current diagnosis and therapeutic options to primarily symptomatic treatment. In addition, bladder targeted drug delivery is challenging due to its unique anatomical features and its natural physiological function of urine storage and frequent voiding. Therefore, current treatment options often fail to provide a highly effective, precisely targeted and long-lasting treatment. With the growing maturity of gene therapy, comprehensive studies are needed to provide a better understanding of the molecular mechanisms underpinning bladder diseases and help to identify novel gene therapeutic targets and biomarkers for treating bladder diseases. In this review, molecular mechanisms involved in pathology of bladder cancer, interstitial cystitis and overactive bladder syndrome are reviewed, with focus on establishing potential novel treatment options. Proposed novel therapies, including gene therapy combined with nanotechnology, localised drug delivery by nanoparticles, and probiotics, are discussed in regard to their safety profiles, efficacy, treatment lenght, precise targeting, and in comparison to conventional treatment methods.
| Type: | Article |
|---|---|
| Title: | Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ejps.2022.106167 |
| Publisher version: | https://doi.org/10.1016/j.ejps.2022.106167 |
| Language: | English |
| Additional information: | Copyright © 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Bladder cancer; Overactive bladder; Interstitial cystitis, Nanoparticles; Probiotics; Gene therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10179037 |
Archive Staff Only
 |
View Item |
